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Lymphodepleting Chemotherapy and Donor
Lymphocyte Infusion for Relapsed Hematologic
Malignancies Postallogeneic Hematopoietic
Cell Transplantation
Erica D. Warlick, Todd DeFor, Bruce R. Blazar, Linda Burns,
Michael R. Verneris, Celalettin Ustun, Daniel J. Weisdorf, Jeffrey S. MillerFew therapeutic strategies exist for hematologic malignancies relapsing post allogeneic hematopoietic cell
transplantation. We present outcomes on 35 patients with nonchronic myelogenous leukemia (CML) hema-
tologic malignancies, the majority having acute myelogenous leukemia (AML) or myelodysplastic syndromes/
myeloproliferative disorders (MDS/MPD) (n 5 22) receiving lymphodepleting chemotherapy followed by
donor lymphocyte infusion (DLI) at 2 T cell dose levels (0.5 and 1.0  108 CD3/kg). Forty-nine percent of
patients achieved complete remission (CR), with a median duration of remission of 6 months (range:
2-711). CR rates were similar between the 2 groups. The incidence of acute graft-versus-host disease
(aGVHD) of any grade was 49%. We saw a higher incidence of grade II-IV aGVHD, with a rate of 66% using
the higher-dose DLI (grade III, 33% and grade 4, 20%) versus only 25% (10% grade III-IV) with the lower-dose
DLI (P5.06).Overall survival at 1 and 2 yearswas 30% (95% confidence interval [CI], 16%-45%) and 19% (95%
CI, 8%-34%); however, for those achievingCR, 1- and 2-year survival was improved at 44% (95%CI, 20%-66%)
and 28% (95% CI, 8%-52%) (P5.03), respectively. These results demonstrate that DLI after lymphodepleting
chemotherapy for relapsed hematologic malignancies results in frequent CRs. The lower DLI dose regimen
improved the tolerability of this therapeutic approach, with modest rates of severe aGVHD.
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Relapse of underlying hematologicmalignancy fol-
lowing allogeneic hematopoietic cell transplant (HCT)
remains a major obstacle for long-term disease-free
survival [1]. Therapeutic options for patients relapsing
with nonchronic myelogenous leukemia (CML) dis-
ease post allogeneic HCT are limited and often unsuc-
cessful. The literature describing responses to donor
lymphocyte infusion (DLI) post allogeneicHCTvaries
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remission status at time of DLI, and use of disease-
specific chemotherapy to reduce the tumor burden
before DLI infusion [2-6]. The initial use of DLI in
patients with CML produced optimism that DLI
alone would be a successful therapy for relapsed
hematologic malignancies given the high (701%)
complete remission (CR) rates [7-9]. However,
responses to DLI in other hematologic malignancies
have been less successful. DLI studies with acute
myelogenous leukemia (AML) patients, with the
majority receiving AML-specific reinduction chemo-
therapy before DLI yield CR rates ranging from 28%
to 65% [4,5,10,11]. The largest of these series
showed improved 2-year survival in those with favor-
able cytogenetics and those in remission at the time
of DLI (56%), thus nearing but not reaching the suc-
cess with DLI for relapsed CML [4]. The discrepant
results between CML and AML/myelodysplastic syn-
drome (MDS) responses are potentially related to the
underlying biology and kinetics of disease or the
differential responsiveness to a graft-versus-leukemia
effect between chronic and acute leukemias. In lym-
phoid malignancies, CR rates following DLI range
from 42% to 76% depending on the underlying dis-
ease, but most reports describe less consistent use of
pre-DLI chemotherapy [2,3,12].
An alternative to disease-specific chemotherapy is
the use of lymphodepleting chemotherapy immedi-
ately followed by DLI in order to alter the immu-
nologic milieu by potentially increasing access to
cytokines and decreasing numbers of T regulatory
cells and myeloid-derived suppressor cells that may in-
hibit DLI function. Initially described by Dudley et al.
[13] in the setting of refractory, heavily pretreated
melanoma, lymphodepleting chemotherapy followed
by adoptive transfer of tumor specific autologous lym-
phocytes was associated with significant responses. At
the University of Minnesota, we used the approach
of lymphodepleting chemotherapy before DLI in re-
lapsed hematologic malignancies and previously re-
ported our 2004 to 2006 [14] experience. Our initial
lymphodepleting regimen included a combination of
fludarabine and cyclophosphomide therapy before
DLI at a dose of 1  108 CD31 cells/kg. We observed
substantial rates of CR in the initial 15 patients; how-
ever, this came at the expense of high rates of grade III-
IV acute graft-versus-host disease (aGVHD), which in
some cases was the cause of death. We report here
updated outcomes on all 35 patients that include an
additional 20 patients treated with the same lympho-
depleting conditioning before a reduced dose of DLI
of 0.5  108 CD31 cells/kg. We show that both regi-
mens are effective at inducing remissions, but that the
lower T cell dose DLI is associated with less severe
aGVHD.PATIENTS AND METHODS
Patients with relapsed hematologic malignancy
post sibling or unrelated donor HCT were eligible
for enrollment. Patients were required to be within
1 year of identification of relapse with at least 10%
donor marrow DNA by chimerism or FISH cytoge-
netics. The same allogeneic transplant donor from
transplantation was used for DLI. Patients were
required to have adequate organ function including
a creatinine#2.0 mg/dL, liver function tests\5 times
the upper limit of normal, a left ventricular cardiac
ejection fraction of .40%, pulmonary functions
.50% of predicted with testing required only if symp-
tomatic or prior known impairment, and chest radio-
graph with no evidence of active infection. Patients
were required to be off immunosuppressive agents
for at least 3 days before DLI infusion and have no
evidence of active GVHD. Karnofsky performance
status was required to be $60%. Patients with active
central nervous system leukemia, active fungal infec-
tions, and human immunodeficiency virus positivity
were excluded.
Donor lymphocytes were collected by lymphophe-
resis the morning of planned DLI (sibling donors) and
at outside institutions according to procedures set by
the National Marrow Donor Program before the day
of DLI to allow for transport of the cells to our
center (adult unrelated donors). Donors received no
priming medications or priming agents before lym-
phopheresis [14].
Before DLI infusion, patients received a lympho-
depleting regimen of intravenous (i.v.) fludarabine
25mg/m2 for 5 consecutive days (26 to22) and cyclo-
phosphamide 60 mg/kg i.v. over 2 hours once on
day25 with 2-mercaptoethane sulfonate and hyperhy-
dration support. The DLI infusion was given on day 0.
Fifteen patients received DLI with a T cell dose of
1 108CD31 cells/kg, as previously reported [14]. Be-
cause of the encouragingCR rates (53%) but high rates
of severe aGVHD (53% grade III and IV) in the initial
DLI dose cohort, the DLI T cell dose was reduced to
0.5  108 CD31 cells/kg for 20 subsequent patients.
Response assessments to chemotherapy and DLI,
with bone marrow biopsy and or CT scan imaging if
indicated, were completed at 1 and 3 months post-
DLI infusion. Repeat assessments for response, sur-
vival, and toxicity continued at 6 months and 1 year,
with ongoing yearly follow-up for 5 years post infusion
for surviving patients.
Patients
The median age of the 35 patients was 51 with
equal gender representation. Fifty-four percent
(n 5 19) of the chemotherapy and DLI occurred
between 2004 and 2006, with the remainder between
Table 1. Patient Characteristics
Factors Total
Total 35
Year of DLI
2004-2006 19
2007-2009 16
Age at transplantation
Median (range), IQR 51 (1-66), (44-58)
DLI dose
1  108 CD 3+/kg 15
0.5  108 CD 3+/kg 20
Gender
Male 18
Female 17
Donor type
Sibling 30
URD 5
Disease
AML 15 (43%)
MDS/MPD 7 (20%)
NHL/Hodgkin’s 5 (14%)
CLL 3 (8.5%)
Multiple myeloma 2 (5.5%)
ALL, prolymphocytic leukemia 3 (9%)
JMML
Disease status at DLI
CR* 3 (8.5%)
Marrow only 22 (63%)
EM disease 7 (20%)
EM + marrow 3 (8.5%)
Months from HCT to relapse (range) 7 (2.7-105)
Follow-up among survivors
Median (range) in years 2.3 (0.3-6.2)
NHL indicates non-Hodgkin lymphoma; CLL, chronic lymphocytic leu-
kemia; ALL, acute lymphocytic leukemia; JMML, juvenile myelomono-
cytic leukemia; URD, unrelated donor; IQR, interquartile range; EM,
extramedullary.
*All 3 patients who entered the trial in CR were AML patients who
received reinduction chemotherapy before enrollment on this trial.
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time periods and DLI dose levels had either AML or
myelodysplastic syndromes/myeloproliferative disor-
ders (MDS/MPD) (63%, n 5 22). Median time from
HCT to relapse for the entire cohort was 211 days
(range: 80-3151); however, there was a slight differ-
ence in time from HCT to relapse between the 2
DLI dose cohorts. Those receiving the higher T cell
dose of 1  108 CD31 cells/kg had a slightly shorter
median time from HCT to relapse of 161 days (range:
80-721), whereas those receiving the 0.5  108 CD31
cells/kg T cell dose had a median time from HCT to
relapse of 248 days (range: 131-3151) (P 5 .03). Data
regarding date of immunosuppression (IS) cessation
before DLI was available in 33 patients. IS was discon-
tinued a median of 66 days before DLI; however, the
range was wide at 14-2014 because of a number of
late posttransplantation relapses. Median follow-up
among survivors for the entire cohort of patients is
2.3 years (range: 0.3-6.2). Patient and transplant char-
acteristics are described in Table 1.
All study procedures, patient samples, and data
collection occurred after obtaining informed consent
using methods approved by the University of Minne-
sota institutional review board and registered at clini-
cal trials.gov as NCT00167180.
Statistics
Patients with non-CML diagnoses were included
in this analysis. Comparison of demographics, patient
characteristics, and toxicities across dose cohorts were
assessed by the chi-square test, Fisher exact test, or the
Wilcoxon test where appropriate [15]. Primary end-
points of the study were to evaluate safety of the lym-
phodepleting preparative regimen when combined
with DLI in relapsed non-CML patients post-HCT
and to test whether lymphodepleting chemotherapy
improved the efficacy of DLI. Cumulative incidence
was used to estimate aGVHD, treating non-GVHD
death as a competing risk [16]. Overall survival (OS)
was estimated using the Kaplan-Meier method [17].
Responses were defined as best response achieved
with classifications of no response/dead, partial re-
sponse (PR), or complete response (CR). Duration of
CR was defined as the time from documented CR
post-DLI until relapse. Patients who relapsed and
then went on to obtain CR after receiving additional
alternative therapy were still defined as relapse with
respect to the chemo-DLI intervention. Response
was statistically compared across categories by the
Fisher exact test. Time to relapse post-HCT (\6
months5 early and$6 months 5 late), site of disease
before chemotherapy and DLI (marrow, extramedul-
lary, or both), and site of disease relapse post-DLI
were also evaluated for impact on outcomes of remis-
sion and subsequent relapse. For the 1 patient who
received a second course of chemotherapy and DLI,analysis of response and duration was determined fol-
lowing the first course.RESULTS
Response
Seventeen of the 35 patients (49%) obtained a CR
following the lymphodepleting chemotherapy and im-
mediate DLI. CR rates were similar when comparing
DLI dose cohorts, comparing patients with early ver-
sus late posttransplantation relapses, comparing
AML/MDS versus other hematologic malignancies,
or comparing site of initial post-HCT disease relapse.
CR rates between the high and low DLI dose cohorts
were similar at 53% and 45%, respectively (P 5 .89).
Rates of CR were not influenced by the time of relapse
posttransplantation (early\6 months versus late $6
months). Of the 12 patients relapsing early, 58% (n
5 7) achieved CR compared with 43% (n 5 10 of
23) for those with later relapse. However, important
to note is that the majority of early relapse patients re-
ceived the high-dose DLI, while the majority of later
relapse patients received the lower-dose DLI.
Figure 1. Grade III-IV aGVHD by DLI dose. Rates of severe aGHVD
grades III-IV based on DLI dose: significantly higher rates in those
patients receiving higher-dose DLI.
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impact CR rates with 50% (n5 11) of AML/MDS pa-
tients compared with 46% (n 5 6) of patients with
other hematologic malignancies obtaining CR (P 5
.97). Last, site of disease relapse post-HCT (extrame-
dullary, bone marrow, or both) had no impact on CR
rates (P 5 .40).
The median duration of CR was 6 months (range:
2-711). A total of 5 patients remained in CR for 12
months or greater, with 3 patients relapsing at 12,
17, and 66 months and 2 patients (1 with multiple my-
eloma, and 1 with chronic lumphocytic leukemia) in
ongoing CR at 24 and 71 months, respectively. Both
patients in ongoing CR received a peripheral blood
stem cell transplant from their male sibling. Both
developed relatively early aGVHD at 44 and 35 days
that transitioned to chronic GVHD (cGVHD) that
required continued IS at last follow-up.
Relapse Postchemo-DLI-Induced CR
Of those 17 patients achieving a complete remis-
sion postchemotherapy and DLI, 9 subsequently
relapsed. The incidence of relapses for the entire
group at 3, 6, and 12 months were 12% (0%-27%,
95% confidence interval [CI]), 36% (12%-60%, 95%
CI), and 56% (29%-83%, 95% CI), respectively. Al-
though CR rates were similar between the early and
post-HCT relapse cohorts, there was a trend toward
improved duration of CR in the patients relapsing
$6 months posttransplantation. Specifically, those
patients who relapsed\6 months posttransplantation
had a median duration of CR of 76 days (range:
20-298) compared with a median duration of CR of
132 days (range: 100-231) for those who relapsed $6
months posttransplantation (P 5 .30). Relapse rates
for patients with AML/MDS were similar to those
with other hematologic malignancies; however, the
tempo to relapse varied slightly between the groups.
At 3 months, the incidence of relapse for AML/MDS
patients was 9% (0%-25%, 95% CI) compared with
17% (0%-44%, 95%CI) for other hematologic malig-
nancies. By 6 months, the incidence of relapse in
the AML/MDS cohort was 39% (9%-69%, 95% CI)
compared with 50% (23%-77%, 95% CI) in the
other hematologic malignancy cohort. However, by
12 months, no additional patients in the other hemato-
logic malignancy cohort relapsed, whereas the inci-
dence increased in the AML/MDS cohort to 60%
(27%-93%, 95% CI).
GVHD
The incidence of aGVHD of any grade following
DLI was 49% with a median time to development of
21 days (range: 9-92). There was no apparent correla-
tion between time from IS cessation to DLI and time
to development of aGVHD, with early aGVHDdevel-oping even in patients with a late posttransplantation
relapse who had been off IS for years.
Severity and incidence of aGVHD differed
between the DLI dose cohorts (P 5 .06). Following
the higher DLI dose, the incidence of aGVHD grade
II-IV was 66% (grade III, 33% and grade 4, 20%). Fol-
lowing the reduced-dose DLI, grade II-IV aGVHD
developed in only 25% (grade III-IV, 10%) (Figure 1).
Acute GVHD was associated with a trend toward
more frequent CR. Sixty-five percent of those with
aGVHD obtained a CR versus only 33% with no
GVHD (P 5 .06). The median duration of CR was
similar with and without aGVHD (6 months [range:
2-711] and 4.5 months (range: 2-66]), respectively.
The incidence of cGVHD for those patients sur-
viving 100 days post-DLI was 18%. The 2 patients
who remain alive and free of underlying hematologic
malignancy have ongoing evidence of cGVHD.
Toxicity
Toxicity was significantly increased in the patients
receiving DLI at a dose of 1  108. As noted above,
a substantially higher rate of grade II-IV aGVHD
was observed in the higher-dose DLI cohort. Reported
grade III-IV toxicities, not including GVHD or death,
were also increased in the higher-dose DLI cohort,
with a total of 10 reported toxicities including diarrhea
(n5 5), rash (n5 2), liver dysfunction (n5 1), pancre-
atic abnormalities (n5 1), and other miscellaneous GI
issues (n5 1). Grade III-IV toxicities were fewer in the
lower-dose DLI cohort totaling 6 including diarrhea
(n5 2), rash (n5 1), liver dysfunction (n5 1), miscel-
laneous gastrointestinal issues (n 5 1), and dermato-
logic abnormalities (n 5 1).
Immune Reconstitution
Mononuclear cell subsets (CD141, CD191,
CD31, CD561/CD32, CD561/CD31) were quanti-
fied in the 2 DLI dose cohorts at baseline, day 114,
and day 128 post-DLI and were similar at all time
Figure 2. One-year survival by response. One-year OS based on
response to DLI. Patients achieving a complete remission had substan-
tially improved 1-year OS.
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41, CD31/81, and natural killer [NK] cells) was mea-
sured as a surrogate biomarker for in vivo proliferation
in the low- and high-DLI cohorts. Compared with the
higher-dose DLI patients, lower-dose DLI patients
had approximately one-half of the CD31/CD41 and
CD31/CD81 lymphocytes proliferating, but differ-
ences were not significant because of the small sample
size. Interestingly, proliferation of NK cells was
slightly greater in the lower-dose DLI cohort, suggest-
ing thatNKcells andT cellsmay compete in a lympho-
deplete environment (data not shown). Given the
similar CR rates between the 2 DLI dose cohorts,
the slight difference in T and NK cell proliferation be-
tween the 2 cohorts did not impact outcome.
Survival
OS at 1 and 2 years was 30% (95% CI, 16%-45%)
and 19% (95% CI, 8%-34%), respectively. Achieve-
ment of CR impacted survival, with 1- and 2-year
OS improved to 44% (95% CI 20%-66%) and
28% (95% CI, 8%-52%) (P 5 .03), respectively
(Figure 2). Timing of initial relapse post-HCT, inter-
estingly, did not correlate with differences in survival.
OS at 1 year was 25% (6%-50%, 95% CI) and 32%
(15%-52%, 95%CI) for the early versus later relapses,
respectively (P 5 .74).
The causes of death were GVHD (n5 7), relapsed
disease (n 5 16), and new malignancy (n 5 1). Acute
GVHD-related death was more frequent in the
higher-dose DLI group (n 5 6 versus 1).DISCUSSION
Relapsed disease after allogeneic HCT for hema-
tologic malignancy remains a challenge with limited
therapeutic options. We have shown that DLI
after lymphodepleting chemotherapy is permissive of
in vivo lymphocyte expansion [14], resulting in fre-
quent CR and promising survival. The initial approach
with higher-dose DLI was hampered by relatively high
rates of severe aGVHD (grade III-IV) and grade II-IV
toxicities, but lower-dose DLI produced only modest
rates of aGVHD without compromise of response.
Post-transplantation therapeutic immune modula-
tion for relapsed hematologic malignancy is changing.
The initial success of DLI alone in CML has been less
effective in other hematologic malignancies. Most re-
cent efforts include debulking chemotherapy followed
by DLI typically using disease-specific chemotherapy
before DLI [4,6,10,11]. We tested a standardized
lymphodepleting chemotherapy approach before DLI
based on the premise of altering the immunologic
milieu to maximize the response to DLI. As others
have shown, lymphodepleting chemotherapy serves
to increase access to lymphoid-stimulating cytokinesand to decrease the numbers of regulatory T cells and
myeloid-derived suppressor cells that may inhibit
DLI function [18]. Compared with earlier reports, we
observed promising CR rates and encouraging survival
in CR patients [4,5,10]. However, in contrast to other
series [4,5], our CR rates or OS were not adversely
impacted by early relapse post-transplantation (defined
as \6 months). In close analysis of the cohort of
patients within the early versus late post-HCT relapse
groups, the majority of patients in the early post-HCT
relapse cohort received the higher-dose DLI and the
majority of the patients in the later relapse cohort
received the lower-dose DLI. Thus, the lack of differ-
ence in CR rates or OSmay be a reflection of the inter-
play between time of posttransplantation relapse and
DLI T cell dose. However, given the similar outcomes
despite timing of post-transplantation relapse, it could
still be argued that the combination of lymphodeplet-
ing chemotherapy followed by DLI may have the
ability to overcome the poor risk feature of early
post-HCT relapse. Although there remain only 2 pa-
tients in sustained remissions, an additional 3 patients
remained in CR for 12 months or greater, suggesting
that the lymphodepleting chemotherapy andDLI ther-
apeutic platform is a valid approach for this high-risk
group of patients.
Acute GVHD following DLI is a potentially life-
threatening complication that can threaten the success
of the intervention, even when CR is obtained. Reduc-
tion in the DLI CD31 dose produced significantly less
frequent and less severe aGVHDwithout compromis-
ing remission rates. Regardless of DLI T cell dose,
aGVHD was associated with improved CR rates. In-
terestingly, our patients developed aGVHD relatively
early post-DLI regardless of the duration of time be-
tween prior IS cessation andDLI infusion. These find-
ings suggest that the lymphodepleting chemotherapy
may alter the cytokine milieu to permit the develop-
ment of early aGVHD. The development of aGVHD
and cGVHD were associated with improved CR rates
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portance of GVHD for success of the therapy.
The immune reconstitution studies showed similar
lymphocyte subsets between the 2 cohorts and slightly
higher CD31 proliferation at day 114 in the higher-
dose cohort and NK cell proliferation in the lower-
dose DLI cohort. However, these differences did not
appear to impact the CR rates and are not able to ex-
plain the absence or presence of aGVHD develop-
ment. The association of GVHD with long-term
response suggests that additional interventions to pro-
mote controlled GVHDmay improve outcome. Addi-
tional therapeutic manipulations to prolong remission
duration could include serial, consolidative DLI infu-
sions, possibly coupled with tumor-sensitizing maneu-
vers such as tumor-specific vaccines or antitumor
antibodies.
Our study has several limitations including small
sample size and heterogeneous patient population.
Additionally, we did not perform bone marrow assess-
ments or disease restaging scans between the chemo-
therapy and the DLI. This limits our ability to
definitively interpret which component of therapy
(the chemotherapy or the DLI) had more of an impact
on remission rates. Despite that, the association of im-
proved outcome withGVHDonset would suggest that
the DLI was the primary determinant of success.
Future studies to measure T regulatory cells and
myeloid-derived suppressor cells pre- and post-
lymphodepleting chemotherapy are warranted and
may help to us to understand the biology of these
responses. Despite these limitations, our study pro-
vides insight into the impact of lymphodepleting
chemotherapy followed immediately by DLI to treat
post-HCT relapse. The importance of GVHD devel-
opment in successful outcomes suggests that the
lymphodepleting chemotherapy enhancesDLI to over-
come the poor risk feature of early post-HCT relapse.
This platform can lead to additional interventions that
may prolong response, but the challenge is to enhance
antitumor immunity without severe GVHD. In sum-
mary, we show that lymphodepleting chemotherapy
followed by DLI for patients with advanced hemato-
logic malignancies relapsing postallogeneic HCT can
be effective therapy, but further interventions to extend
post-DLI remissions, such as repeat DLI, vaccine ther-
apies, or immune modulation with histone deacetylase
inhibitors to augment the immune impact, will be
important to further improve efficacy.ACKNOWLEDGMENTS
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33:1-7.Sequential Bortezomib, Dexamethasone, and
Thalidomide Maintenance Therapy after
Single Autologous Peripheral Stem Cell
Transplantation in Patients with Multiple Myeloma
Firoozeh Sahebi,1,5 Paul H. Frankel,2 Len Farol,1,5 Amrita Y. Krishnan,1 Ji-lian Cai,1,5
George Somlo,1 Sandra H. Thomas,1 Eunicia Reburiano,1
Leslie L. Popplewell,1 Pablo M. Parker,1 Ricardo T. Spielberger,1,5
Neil M. Kogut,1,5 Chatchada Karanes,1 Myo Htut,1 Christopher Ruel,2
Lupe Duarte,2 Joyce L. Murata-Collins,4 Stephen J. Forman1We report feasibility and response results of a phase II study investigating prolonged weekly bortezomib and
dexamethasone followed by thalidomide and dexamethasone as maintenance therapy after single autologous
stem cell transplantation (ASCT) in patients with multiple myeloma. Within 4 to 8 weeks of ASCT, patients
received weekly bortezomib and dexamethasone for six cycles, followed by thalidomide and dexamethasone
for six more cycles. Thalidomide alone was continued until disease progression. Forty-five patients underwent
ASCT. Forty patients started maintenance therapy; of these, 36 patients received four cycles, and 32 completed
six cycles of maintenance bortezomib. Of these 40 patients, nine (22%) were in complete response (CR) before
ASCT, 13 (32%) achieved CR after ASCT but before bortezomib maintenance therapy, and 21 (53%) achieved
CR after bortezomib maintenance therapy. Nine patients not previously in CR (33%) upgraded their response
to CR with bortezomib maintenance. At 1 year post-ASCT, 20 patients achieved CR, and two achieved very
good partial response. Twenty-seven patients experienced peripheral neuropathy during bortezomib therapy,
all grade 1 or 2. Our findings indicate that prolonged sequential weekly bortezomib, dexamethasone, and tha-
lidomide maintenance therapy after single ASCT is feasible and well tolerated. Bortezomib maintenance treat-
ment upgraded post-ASCT CR responses with no severe grade 3/4 peripheral neuropathy.
Biol Blood Marrow Transplant 18: 486-492 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Post-transplant, Proteasome inhibitor, Immunomodulatory drug, IMiDINTRODUCTION
Despite recent advances in the treatment of multi-
ple myeloma using novel agents and autologous stem
cell transplantation (ASCT), the disease remains
incurable, with persistent disease as the main cause oftreatment failure. The quality and depth of response
to treatment, particularly the achievement of complete
response (CR) or very good partial response (VGPR),
is associated with significant improvement in
progression-free survival (PFS) and overall survival
(OS) in patients with multiple myeloma [1,2]. In
addition, durability of response is also known to
improve long-term outcome [3].
Consolidation and/or maintenance therapy have
been under investigation for the past 3 decades as
a means of improving response, disease control, and
ultimately survival. Studies using thalidomide, a first-
in-class immunomodulatory drug, either alone or in
combinationwith steroids asmaintenance therapy after
single or double ASCT have consistently reported im-
proved PFS [4-7], supporting the use of post-ASCT
